RE: Short Term Key Stategic Priorities6 May 2024 14:36
What do we know so far:
1) Its all about AVA6000 (and perhaps Affyxcel)
MOSTLY......
2) The Initial Phase 1 trial (3 weekly dosing) overran terribly and the dosing interval appears to have been sub-optimal.
YOUR ASSUMPTION ABOUT SUB OPTIMAL MAKING UP YOUR OWN NARRATIVE....
3) They changed mid-trial to have a 2 weekly dosing arm and at this stage the Chief Development Officer (Neil Bell) left without explanation. Culpable or disagreed?
AGAIN YOUR ASSUMPTION OF WHAT YOU THINK. THE ACTUAL Trial WAS WORKING BETTER THAN EXPECTED SO MOVED TO 2 WEEK DOSING. I SEE THAT AS GOOD.
DR BELL WAS A CONSULTANT ANT THEY ALL MOVE ON
---MY ASSUMPTION AND OPINION
4) They sorted ongoing funding via an increasingly onerous Heights Loan Noted deal.
AGREE AT THE TIME LOOKED GOOD BUT WITH HINDISGHT NOT A GOOD MOVE.
CANNOT REMEMBER YOU OR YOUR ALTER EGO SAYING IT WAS A BAD MOVE...
MY OPINION.
5) True to form the 2 weekly trial is already missing deadlines.
YOU HAVE A BEE IN YOUR BONNET ABOUT THIS BUT IT IS A GAME CHANGER AND OBS YOU ARE THICK AS MINCE.
EVEN AVACTA CANNOT DICTATE WHAT PATIENTS ON ANY TRIAL MAY OR MAY NOT DO OR REACT AND HAVE OTHER REASONS. THIS IS A REAL LIFE TRIAL AND LOKE ALL OTHER TRIALS IS PRONE TO TIMELINE ISSUES GIVEN WHO AND WHAT AVACTA ARE DOING.
6) The recent Fund Raise was far from a success. A small amount that wasn't enough to clear the Heights funding not fund AVA6000 through to completion, indeed only 'into' Phase 2.
STATING WHAT NEARLY ALL OF US AGREE WITH. SO DITTO
7) As Wyn says the size of the raise and the heavy discount is not indicative of compelling data at this point, or possibly at any time in the near future?
NO PROOF TO THAT CONCLUSION. I COULD ALSO THROW ONE IN BASED AROUND CORRUPTION AND DEUTCHE BANK EMPLOYEES OR SIMILAR SHORTERS THAT ARE ON A MISSION TO DEPRESS THE SP WHICH THEY HAVE ATTACKED NOW FOR NEARLY 2 YEARS
8) And then the CEO was forced out and a relatively new employee was 'fast tracked' into the post. No one else interested?
EVERYONE HAS AN OPINION ON THIS. READ BETWEEN THE LINES AND IT IS Obvious THAT IS POTENTIALLY ONLY CC IS INTERIM.
THEY HAVE CONCLUDED THE TEAM NEEDS BOLSTERING WITH PERSONNEL WHO WILL DRIVE THE PRODUCT TO MARKET AND THEOUGH THE TRIAL TO DEALS THAT ARE ALREADY BEING DISCUSSED.
9) Why no LG update? If they're still working on this then we should be told. Worryingly the RNS page is littered with historic RNSs of deals made than then are simply never mentioned again. Is LG about to join this group too?
IT IS ONGOING. IF THEY ARE STILL WORKING ON THIS THEN WHY UPDATE UNTIL THEY HAVE NEWS
10) Likewise Affimers and antibody mimetics, 'drugable pockets' etc etc. All the other things that we might be doing but don't appear to be. Where's the information?
IM SURE AFFIMERS HAVE BEEN COMMUNICATED IN RECENT RNSs...But you assume yet again your own narrative.
You see an SP which is at a low. It has been attacked TW factual proof and now some